Orthocell Limited
Orthocell Limited (OCC.AX) Financial Performance & Income Statement Overview
Review Orthocell Limited (OCC.AX) income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Orthocell Limited (OCC.AX) Income Statement & Financial Overview
Analyze Orthocell Limited’s OCC.AX earnings with segmented quarterly and yearly financial statement figures.
| Metric | Q4 2024 | Q2 2024 | Q4 2023 | Q2 2023 |
|---|---|---|---|---|
| Revenue | $3.91M | $2.56M | $3.40M | $846859.00 |
| Cost of Revenue | $821851.00 | $764828.00 | $671010.00 | $511350.00 |
| Gross Profit | $3.09M | $1.79M | $2.73M | $335509.00 |
| Gross Profit Ratio | $0.79 | $0.70 | $0.80 | $0.40 |
| R&D Expenses | $4.83M | $3.84M | $4.02M | $3.58M |
| SG&A Expenses | $2.83M | $3.89M | $3.69M | $2.12M |
| Operating Expenses | $7.67M | $7.73M | $7.71M | $5.69M |
| Total Costs & Expenses | $8.49M | $8.50M | $8.38M | $6.21M |
| Interest Income | $505380.00 | $526301.00 | $728226.00 | $122567.00 |
| Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 |
| Depreciation & Amortization | $277022.00 | $240055.00 | $310548.00 | $243573.00 |
| EBITDA | -$4.73M | -$5.52M | -$5.04M | -$3.81M |
| EBITDA Ratio | -$1.21 | -$2.23 | -$1.38 | -$6.04 |
| Operating Income | -$4.58M | -$5.94M | -$4.98M | -$5.36M |
| Operating Income Ratio | -$1.17 | -$2.32 | -$1.47 | -$6.33 |
| Other Income/Expenses (Net) | -$423614.00 | $710905.00 | -$372513.00 | $1.30M |
| Income Before Tax | -$5.002M | -$5.23M | -$5.35M | -$4.06M |
| Income Before Tax Ratio | -$1.28 | -$2.05 | -$1.58 | -$4.79 |
| Income Tax Expense | -$3.05M | $5.00 | -$3.16M | -$3.00 |
| Net Income | -$1.95M | -$5.23M | -$2.19M | -$4.06M |
| Net Income Ratio | -$0.50 | -$2.05 | -$0.65 | -$4.79 |
| EPS | -$0.01 | -$0.03 | -$0.01 | -$0.02 |
| Diluted EPS | -$0.010 | -$0.03 | -$0.01 | -$0.02 |
| Weighted Avg Shares Outstanding | $193.79M | $199.27M | $197.30M | $193.17M |
| Weighted Avg Shares Outstanding (Diluted) | $202.86M | $199.27M | $197.30M | $193.17M |
The company's financials show resilient growth, with revenue advancing from $846859.00 in Q2 2023 to $3.91M in Q4 2024. Gross profit remained healthy with margins at 79% in Q4 2024 compared to 40% in Q2 2023. Operating income hit -$4.58M last quarter, sustaining a consistent -117% margin. Changes in R&D and SG&A spending did not hinder EBITDA, which stood at -$4.73M. Net income rose to -$1.95M, while earnings per share reached -$0.01. Strong cost management and operational efficiency kept profitability intact, underlining the company's stable and competitive market performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan